Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2016

Summary of Significant Accounting Policies

Schedule of Property Plant and Equipment Useful Lives

Buildings	20 years
Building improvements	5 ‑ 20 years
Software, machinery and equipment	1 ‑ 15 years

Schedule of components of the calculations of basic and diluted earnings per share:

The following table provides the components of the calculations of basic and diluted earnings per share (in thousands, except share amounts):

	Year ended December 31,
	2016		2015			2014
Numerator:
Net loss attributable to common shareholders	$	(57,591)	$	(55,795)	$	(88,644)
Denominator:
Weighted average number of common shares outstanding		180,619,860		176,067,231		159,228,815

Schedule of dilutive potential common shares

	At December 31,
	2016	2015	2014
Stock options outstanding (1)	14,760,054	11,700,786	8,367,271
Restricted stock outstanding	13,333	204,444	473,336
Common stock warrants (2)	14,501,600	4,192,567	4,219,449
Preferred stock (3)	17,490,078	5,554,594	5,554,594
Number of dilutive potential common shares	46,765,065	21,652,391	18,614,650

(1) During the years ended December 31, 2016, 2015, and 2014 the Company granted 3,702,500,  3,960,000 and 4,245,000 stock options, respectively.

(2) In May 2011, the Company issued 7,128,563 warrants as part of an underwritten public offering with an exercise price of $0.93 per warrant.  As a result of additional public offerings, and pursuant to the effect of the anti-dilution provisions of these warrants, the number of warrants increased to 22,995,365.  Of these warrants issued in May 2011, zero,  192,467, and 219,349 were unexercised as of December 31, 2016, 2015, and 2014 respectively.

In February 2013, the Company issued 23,637,500 warrants as part of an underwritten public offering with an exercise price of $0.15 per warrant.  Of these warrants issued in February 2013, 100 were unexercised as of December 31, 2016, 2015 and 2014.

In January 2014, the Company issued 4,000,000 warrants as part of an underwritten public offering with an exercise price of $4.00 per warrant.  In December 2016, as a result of additional public offerings, and pursuant to the effect of the anti-dilution provisions of these warrants, the exercise price of the $4.00 warrants was reduced to $1.025. Of these warrants issued in January 2014, none have been exercised as of  December 31, 2016, 2015 and 2014. 

In December 2016, the Company issued 10,501,500 warrants as part of two concurrent underwritten public offerings with an exercise price of $1.50 per warrant.  Of these warrants issued in December 2016, none have been exercised as of December 31, 2016. All warrants have anti-dilution provisions. 

(3) The preferred stock amount represents the dilutive potential common shares of the Series C and D redeemable preferred stock, based on the conversion price of the preferred stock as of December 31, 2016, 2015 and 2014, respectively.  Of the 10,431 Series C redeemable preferred stock issued on May 16, 2013, 5,200 had been converted to common stock during the year ended December 31, 2013 with the remainder still outstanding. Of the 18,500 Series D redeemable preferred stock issued on December 22, 2016, zero have been converted to common stock as of December 31, 2016.